Value of single and combined detection of serum pro-gastrin-releasing peptide, alpha fetoprotein and carbohydrate antigen 199 in diagnosis of ovarian cancer

doi:10.16150/j.1671-2870.2019.02.017

Abstract

Abstract:

Objective: To investigate the value of single detection of serum pro-gastrin-releasing peptide (ProGRP), α-fetoprotein (AFP), carbohydrate antigen 199 (CA199), carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4) and combined detection of ProGRP, AFP and CA199 for the diagnosis of ovarian cancer. Methods: Three hundred and seventy nine suspected ovarian cancer patients, including 123 pathologically confirmed cases, admitted from January 2014 to February 2017 and another 256 patients with non-ovarian cancer served as control group were analyzed retrospectively. Serum levels of ProGRP, AFP, CA199, CA125, HE4 in the two groups were compared, and the diagnostic efficacy of single detection of ProGRP, AFP, CA199, CA125, HE4 and combined detection of ProGRP, AFP, CA199 for ovarian cancer was analyzed. ROC curves were plotted based on ProGRP, AFP, CA199, CA125, HE4, and ProGRP, AFP, CA199 combined detection. The AUC under the ROC curve were calculated. Results: The levels of serum ProGRP, AFP and CA199 in patients with stage Ⅰ and Ⅱ of the ovarian cancer were significantly lower than those in stage Ⅲ and Ⅳ(P<0.05). The levels of serum ProGRP, AFP, CA199, CA125 and HE4 of ovarian cancer group were significantly higher than those of the non-ovarian cancer group (P<0.05). The optimal cutoff values of serum ProGRP, AFP, CA199, CA125 and HE4 for diagnosis of ovarian cancer were 69.21 pg/mL, 28.95 ng/mL, 42.38 U/mL, 57.65 U/mL and 125.64 pmol/L, respectively, and the sensitivity of serum ProGRP, AFP, CA199, CA125, HE4 single detection and the combined detection of ProGRP, AFP and CA199 were 78.05%, 80.49%, 85.37%, 88.62%, 91.06% and 77.24%, respectively, the specificity were 85.94%, 86.72%, 87.89%, 90.63%, 90.23% and 97.27%, respectively, the detection accuracy were 83.37%, 84.70%, 87.07%, 89.97%, 90.50% and 90.77%, respectively. The AUC of serum ProGRP, AFP, CA199, CA125, HE4 and combined detection of ProGRP, AFP and CA199 were 0.786, 0.821, 0.897, 0.912, 0.926 and 0.948, respectively. Conclusions: Serum ProGRP, AFP, CA199, CA125, HE4 detection and combined detection of ProGRP, AFP and CA199 all have good performance in the diagnosis of ovarian cancer, and the reliability of combined detection of ProGRP, AFP and CA199 is better, which could be used for screening of ovarian cancer.

Key words: Pro-gastrin-releasing peptide, Alpha fetoprotein, Carbohydrate antigen 199, Ovarian cancer, Diagnostic value

CLC Number:

R737.31

JIANG Dongkui, CHEN Zhaoya, MA Dongmei, XU Lin, RAO Qun. Value of single and combined detection of serum pro-gastrin-releasing peptide, alpha fetoprotein and carbohydrate antigen 199 in diagnosis of ovarian cancer[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(2): 209-214.

Figures/Tables 4

References 30

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
[2]	狄文, 胡媛. 卵巢癌的大数据研究[J]. 中国实用妇科与产科杂志, 2018, 34(1):18-22.
[3]	梁凡, 陈亚萍, 杨恭. 癌间质细胞与卵巢癌治疗相关性研究进展[J]. 中国癌症杂志, 2016, 26(4):351-357.
[4]	李金航, 刘慧, 刘爱军. 卵巢癌铂类药物耐药分子机制研究进展[J]. 中国妇产科临床杂志, 2018, 19(2):184-186.
[5]	Yeganeh PN, Richardson C, Bahrani-Mostafavi Z, et al. Dysregulation of AKT3 along with a small panel of mRNAs stratifies high-grade serous ovarian cancer from both normal epithelia and benign tumor tissues[J]. Genes Cancer, 2017, 8(11-12):784-798.
[6]	薛添, 李艳红, 李铮. 卵巢癌生物标志物的糖链谱研究进展[J]. 生物化学与生物物理进展, 2017, 44(10):865-876.
[7]	李华, 王波, 纪冬梅. 血清ProGRP、HE4、CYFRA21-1在肺癌诊断中的应用及其与病理特征的关系[J]. 癌症进展, 2016, 14(12):1235-1238.
[8]	樊冬梅, 史惠蓉, 陈志敏, 等. 卵巢癌组织中胃泌素释放肽及其受体的表达[J]. 郑州大学学报(医学版), 2011, 46(4):550-553.
[9]	牛茜, 杨爱军, 王晨昱, 等. 前胃泌素在人胃癌BGC-823细胞的悬浮肿瘤球中的表达[J]. 第三军医大学学报, 2011, 32(13):1396-1399.
[10]	詹颉, 常宁宁, 李小侠, 等. CEA,AFP,CA125, CA199和CA72-4联合检测在鉴别卵巢良恶性疾病中的应用价值[J]. 现代检验医学杂志, 2015, 30(5):50-52,55.
[11]	杨会生, 王韩, 汤宛莹, 等. 联合检测CA724、CA199、CEA对胃癌诊断价值的Meta分析[J]. 肿瘤学杂志, 2015, 21(9):714-720.
[12]	谢辛, 苟文丽. 妇产科学[M]. 8版. 人民卫生出版社, 2013:323-324.
[13]	Reed N, Millan D, Verheijen R, 等. 欧洲肿瘤内科协会对非上皮性卵巢癌的诊断、治疗和随访所制定的临床实践指南[J]. 国际妇产科学杂志, 2011, 38(4):339-342.
[14]	Jones HM, Fang Z, Sun 1, et al. Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro[J]. Am J Cancer Res, 2017, 7(12):2478-2490.
[15]	刘佳宇, 赵妍蕊, 张丽娜, 等. 上皮源性卵巢癌中4种miRNAs的表达及其临床意义[J]. 天津医药, 2015, 43(9):996-1000.
[16]	Cree IA. Liquid biopsy for cancer patients: Principles and practice[J]. Pathogenesis, 2015, 2(2):1-4.
[17]	黄宗华, 徐丹丹, 张飞艳, 等. 血清ProGRP和NSE对评价小细胞肺癌化疗疗效及其预后的价值[J]. 中华肿瘤防治杂志, 2015, 22(22):1774-1778.
[18]	Bevilacqua V, Chan MK, Chen Y, et al. Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort[J]. Clin Chem, 2014, 60(12):1532-1542.
[19]	翟婷婷, 李翠芬. 血清CA125、CA199、CEA 和 AFP 联合诊断卵巢癌的临床研究[J]. 现代肿瘤医学, 2015, 23(9):1270-1272.
[20]	周敏巧, 梁文霞, 郑君珍. 血清癌抗原125、甲胎蛋白、癌胚抗原联合检测对女性恶性肿瘤的诊断价值[J]. 中国性科学, 2015, 24(1):55-57.
[21]	屈明利, 邓晓红, 赵侃侃, 等. 血清CA125、CEA、AFP联合检测在卵巢恶性肿瘤诊断中的临床价值[J]. 实用癌症杂志, 2017, 32(7):1065-1068.
[22]	孙蓓, 刘亚红. CA199、CA125和YKL40单项与联合检测在卵巢上皮性肿瘤临床诊断中价值比较[J]. 中南医学科学杂志, 2015, 43(6):651-654.
[23]	李秀华, 冯梅, 钟沛霖, 等. 血清HE4联合CA125、CA199检测对上皮性卵巢癌的诊断价值[J]. 宁夏医科大学学报, 2015, 37(8):959-962.
[24]	陈蓉, 彭必江. 血清人附睾蛋白、CA125、CA199联合检测诊断妇科恶性肿瘤的价值[J]. 医学临床研究, 2017, 34(2):321-323.
[25]	许海, 刘莹. 血清CA199、CA125及AFP联合检测在宫颈肿瘤诊断中的应用研究[J]. 热带医学杂志, 2015, 15(6):766-769.
[26]	王浩, 田田, 李家军, 等. NSE与proGRP单独或并联联合检测对SCLC诊断价值的系统评价[J]. 肿瘤学杂志, 2017, 23(9):765-771.
[27]	Nazmeen A, Maiti S, Mandal K, et al. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease[J]. Med Chem, 2017, 13(8):796-804.
[28]	付伟, 王松, 米祖云, 等. 联合检测血清CA125、CA199在消化系统恶性肿瘤诊断中的价值[J]. 现代肿瘤医学, 2017, 25(21):3468-3470.
[29]	李克敏, 宋亮, 尹如铁. 2017年第4版NCCN卵巢癌临床实践指南解读[J]. 华西医学, 2018, 33(4):398-402.
[30]	张靖, 白惠娟. 卵巢癌腹腔热灌注化疗临床效果及血清CA125水平变化[J]. 安徽医学, 2017, 38(9):1169-1171.

组别	n	ProGRP（pg/mL）	AFP（ng/mL）	CA199（U/mL）
Ⅰ期	38	104.95±8.37	58.79±5.89	103.94±7.69
Ⅱ~Ⅳ期	85	136.51±11.38	72.32±9.88	135.63±12.41
t值		15.238	8.179	14.525
P值		<0.001	<0.001	<0.001

组别	例数	ProGRP（pg/mL）	AFP（ng/mL）	CA199（U/mL）	CA125（U/mL）	HE4（pmol/L）
卵巢癌组	123	126.76±14.53	68.14±10.36	125.84±14.39	341.47±50.68	259.32±45.27
非卵巢癌组	256	58.16±9.47	6.14±1.12	24.35±4.61	65.42±11.38	54.37±10.36
t值		55.057	94.740	102.543	83.011	68.869
P值		<0.001	<0.001	<0.001	<0.001	<0.001